Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/4052
Title: Pediatric Staphylococcus aureus Bacteremia: Clinical Spectrum and Predictors of Poor Outcome
Authors: McMullan, Brendan
Mowlaboccus, Shakeel
Ojaimi, Samar
Tai, Alex
Vasilunas, Nan
Blyth, Christopher C.
Nourse, Clare 
Bowen, Asha C.
Campbell, Anita J.
Al Yazidi, Laila S.
Phuong, Linny K.
Leung, Clare
Best, Emma J.
Webb, Rachel H.
Voss, Lesley
Athan, Eugene
Britton, Philip N.
Bryant, Penelope A.
Butters, Coen T.
Carapetis, Jonathan R.
Ching, Natasha S.
Coombs, Geoffrey W.
Daley, Denise A.
Francis, Joshua R.
Hung, Te-Yu
Issue Date: 2022
Source: 74, (4), 2022, p. 604-613
Pages: 604-613
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Abstract: Background: Staphylococcus aureus is a common cause of bacteremia, yet the epidemiology and predictors of poor outcome remain inadequately defined in childhood.; Methods: ISAIAH (Invasive Staphylococcus aureus Infections and Hospitalizations in children) is a prospective, cross-sectional study of S. aureus bacteremia (SAB) in children hospitalized in Australia and New Zealand over 24 months (2017-2018).; Results: Overall, 552 SABs were identified (incidence 4.4/100 000/year). Indigenous children, those from lower socioeconomic areas and neonates were overrepresented. Although 90-day mortality was infrequent, one-third experienced the composite of: length of stay >30 days (26%), intensive care unit admission (20%), relapse (4%), or death (3%). Predictors of mortality included prematurity (adjusted odds ratio [aOR],16.8; 95% confidence interval [CI], 1.6-296.9), multifocal infection (aOR, 22.6; CI, 1.4-498.5), necrotizing pneumonia (aOR, 38.9; CI, 1.7-1754.6), multiorgan dysfunction (aOR, 26.5; CI, 4.1-268.8), and empiric vancomycin (aOR, 15.7; CI, 1.6-434.4); while infectious diseases (ID) consultation (aOR, 0.07; CI .004-.9) was protective. Neither MRSA nor vancomycin trough targets impacted survival; however, empiric vancomycin was associated with nephrotoxicity (OR, 3.1; 95% CI 1.3-8.1).; Conclusions: High SAB incidence was demonstrated and for the first time in a pediatric setting, necrotizing pneumonia and multifocal infection were predictors of mortality, while ID consultation was protective. The need to reevaluate pediatric vancomycin trough targets and limit unnecessary empiric vancomycin exposure to reduce poor outcomes and nephrotoxicity is highlighted. One in 3 children experienced considerable SAB morbidity; therefore, pediatric inclusion in future SAB comparator trials is paramount to improve outcomes. (© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)Grant Information: APP1133670 National Health and Medical Research Council Date of Electronic Publication: 20220301. Current Imprints: Publication: Jan. 2011- : Oxford : Oxford University Press; Original Imprints: Publication: Chicago, IL : The University of Chicago Press, c1992-
DOI: 10.1093/cid/ciab510
Resources: https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,athens&db=mdc&AN=34089594&site=ehost-live
Keywords: Humans;Infant, Newborn;Prospective Studies;Retrospective Studies;Staphylococcus aureus;Staphylococcus aureus*;bacteremia*;mortality*;outcomes*;pediatrics*;Child;Anti-Bacterial Agents/therapeutic use;Staphylococcal Infections*/epidemiology;Bacteremia*/drug therapyMethicillin-Resistant Staphylococcus aureus*;Staphylococcal Infections*/drug therapy;Cross-Sectional Studies
Type: Article
Appears in Sites:Children's Health Queensland Publications

Show full item record

Page view(s)

122
checked on Mar 18, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.